Dosing and uses of TNFerade (tumor necrosis factor-alpha (TNF-alpha) adenovector)
Pancreatic Cancer
Investigational/Orphan Status
Intratumoral injections
Other Information
Intratumoral injection for pancreatic cancer guided by endoscopic ultrasound
Other Indications & Uses
Investigational: head & neck cancer, esophageal cancer, rectal cancer
Pediatric dosage forms and strengths
Safety & efficacy not established
TNFerade (tumor necrosis factor-alpha (TNF-alpha) adenovector) adverse (side) effects
Frequency not defined
Data limited, unknown
Warnings
Data limited, unknown
Pregnancy and lactation
Pregnancy category: unknown, avoid pregnancy
Lactation: Unknown if excreted in breast milk, do not breast feed
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of TNFerade (tumor necrosis factor-alpha (TNF-alpha) adenovector)
Mechanism of action
Adenovector (DNA carrier) that contains the gene for tumor necrosis factor-alpha (TNF-alpha), an immune system protein with potent and well-documented anticancer effects
